Notice That HRSA Will Not Fund HRSA-20-083: Quality Improvement Solutions for Sustained Epidemic Control Project, 62312-62313 [2020-21779]

Download as PDF 62312 Federal Register / Vol. 85, No. 192 / Friday, October 2, 2020 / Notices TABLE 1—RECIPIENTS AND AWARD AMOUNTS Award recipient name UCSF–U1NHA31422 .................................................... The Regents of the University of California San Francisco. Trustees of Columbia University in the City of New York. ICAP–U1NHA28555 ..................................................... Justification: The purpose of these cooperative agreements is to save lives, prevent HIV infections, and accelerate progress toward achieving HIV/AIDS epidemic control in more than 50 countries around the world. Recipients have completed certain project activities, but evaluation and transition to scale-up has been interrupted by the COVID–19 pandemic and associated country-specific restrictions. This notice extends the current project period for HRSA–15–021, Quality Improvement Capacity for Impact Project, by one year until September 29, 2021, to ensure the orderly conclusion of these projects while facilitating virtual stakeholder engagement during the COVID–19 pandemic. Authority: United States President’s Emergency Plan for AIDS Relief authorized by Public Law 108–25 (the United States Leadership Against HIV/ AIDS, Tuberculosis and Malaria Act of 2003) [22 U.S.C. 7601, et seq.]; and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), as reauthorized and amended by Public Law 113–56 (the President’s Emergency Plan for AIDS Relief Stewardship and Oversight Act of 2013). See, e.g., 22 U.S.C. 7603 and 22 U.S.C. 2151b–2(b) (1)(B), 2151b–2(c)(1), and 2151b– 2(d)(6)(G)(ii). Thomas J. Engels, Administrator. [FR Doc. 2020–21778 Filed 10–1–20; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration jbell on DSKJLSW7X2PROD with NOTICES Extension length Grant number Recharter for the Council on Graduate Medical Education Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). AGENCY: ACTION: Notice of recharter. VerDate Sep<11>2014 19:38 Oct 01, 2020 Jkt 253001 In accordance with the Federal Advisory Committee Act, HHS is hereby giving notice that the Council on Graduate Medical Education (COGME) has been rechartered. The effective date of the renewed charter is September 30, 2020. FOR FURTHER INFORMATION CONTACT: Shane Rogers, Designated Federal Official (DFO), Division of Medicine and Dentistry, Bureau of Health Workforce, HRSA. Anyone requesting information may reach Mr. Rogers by mail at 5600 Fishers Lane, 15N142, Rockville, Maryland 20857; by phone at 301–443–5260; or by email at SRogers@ hrsa.gov SUPPLEMENTARY INFORMATION: COGME makes recommendations to the Secretary of HHS (Secretary) and Congress on matters specified by section 762 of Title VII of the Public Health Service (PHS) Act. Issues addressed by COGME include (1) the supply and distribution of physicians in the United States; (2) current and future shortages or excesses of physicians in medical and surgical specialties and subspecialties; (3) issues relating to foreign medical school graduates; (4) appropriate federal policies with respect to the matters specified in (1), (2), and (3) above, including policies concerning changes in the financing of undergraduate and graduate medical education (GME) programs and changes in the types of medical education training in GME programs; (5) appropriate efforts to be carried out by hospitals, schools of medicine, schools of osteopathic medicine, and accrediting bodies with respect to the matters specified in (1), (2), and (3) above, including efforts for changes in undergraduate and GME programs; and (6) deficiencies in, and needs for improvements in, existing databases concerning the supply and distribution of, and postgraduate training programs for, physicians in the United States and steps that should be taken to eliminate those deficiencies. Not later than September 30, 2023, and not less than every 5 years thereafter, COGME shall submit a report with recommendations to the Secretary, and to the Committee on Health, Education, Labor, and Pensions of the Senate and SUMMARY: PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 Award amount 1 Year $4,000,000 1 Year 2,000,000 the Committee on Energy and Commerce of the House of Representatives. Additionally, COGME encourages entities providing GME to conduct activities to voluntarily achieve the recommendations of COGME; and develops, publishes, and implements performance measures, develops and publishes guidelines for longitudinal evaluations, and recommends appropriation levels for certain programs under Title VII of the PHS Act. The renewed charter for COGME was approved on September 30, 2020, which will also stand as the filing date. Recharter of the COGME gives authorization for the Council to operate until September 30, 2022. A copy of the COGME charter is available on the COGME website at https://www.hrsa.gov/sites/default/files/ hrsa/advisory-committees/graduatemedical-edu/cogme-charter.pdf. A copy of the charter also can be obtained by accessing the FACA database that is maintained by the Committee Management Secretariat under the General Services Administration. The website address for the FACA database is https://www.facadatabase.gov/. Maria G. Button, Director, Executive Secretariat. [FR Doc. 2020–21773 Filed 10–1–20; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Notice That HRSA Will Not Fund HRSA–20–083: Quality Improvement Solutions for Sustained Epidemic Control Project Health Resources and Services Administration (HRSA), Department of Health and Human Services. AGENCY: ACTION: Notice. HRSA has decided not to provide funding for HRSA–20–083 Quality Improvement Solutions for Sustained Epidemic Control Project, SUMMARY: E:\FR\FM\02OCN1.SGM 02OCN1 Federal Register / Vol. 85, No. 192 / Friday, October 2, 2020 / Notices supported by the President’s Emergency Plan for AIDS Relief (PEPFAR). FOR FURTHER INFORMATION CONTACT: Austin Demby, Ph.D., MPH, Acting Director, Office of Global Health, Office of the Administrator, HRSA, 5600 Fishers Lane, 09N09, Rockville, MD 20857, Phone: (301) 443–0581, Email: ademby@hrsa.gov. SUPPLEMENTARY INFORMATION: Justification: HRSA has decided not to award funding under HRSA–20–083, Quality Improvement Solutions for Sustained Epidemic Control Project, which was published in Fiscal Year 2020. HRSA will consider the needs of the government and the program, and may publish an updated project Notice of Funding Opportunity for a new competitive cycle in Fiscal Year 2021. Authority: United States PEPFAR authorized by Public Law 108–25 (the United States Leadership Against HIV/AIDS, Tuberculosis and Malaria Act of 2003) [22 U.S.C. 7601, et seq.]; and Public Law 110– 293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), as reauthorized and amended by Public Law 113–56 (the PEPFAR Stewardship and Oversight Act of 2013). See, e.g., 22 U.S.C. 7603 and 22 U.S.C. 151b–2(b)(1)(B), 2151b–2(c)(1), and 2151b– 2(d)(6)(G)(ii). [FR Doc. 2020–21779 Filed 10–1–20; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health jbell on DSKJLSW7X2PROD with NOTICES Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. 19:38 Oct 01, 2020 Dated: September 29, 2020. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–21863 Filed 10–1–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Thomas J. Engels, Administrator. VerDate Sep<11>2014 Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Genomic Predictors of Pregnancy Loss. Date: November 20, 2020. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Child Health and Human Development, 6710B Rockledge Drive, Bethesda, MD 20892 (Video Assisted Meeting). Contact Person: Peter Zelazowski, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6710B Rockledge Drive, Bethesda, MD 20892–7510, 301–435–6902, peter.zelazowski@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.865, Research for Mothers and Children, National Institutes of Health, HHS) Jkt 253001 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01). Date: October 28, 2020. Time: 12:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G42B, Rockville, MD 20892 (Virtual Meeting). Contact Person: Louis A. Rosenthal, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 62313 National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G42B, Bethesda, MD 20892–9834, (240) 669–5070, rosenthalla@ niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: September 28, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–21770 Filed 10–1–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Heart, Lung, and Blood Initial Review Group. NHLBI Mentored Clinical and Basic Science Review Committee. Date: November 5–6, 2020. Time: 11:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20814, (Virtual Meeting). Contact Person: Keith A Mintzer, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Suite 207–G, Bethesda, MD 20892–7924, (301) 827–7949, mintzerk@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) E:\FR\FM\02OCN1.SGM 02OCN1

Agencies

[Federal Register Volume 85, Number 192 (Friday, October 2, 2020)]
[Notices]
[Pages 62312-62313]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-21779]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration


Notice That HRSA Will Not Fund HRSA-20-083: Quality Improvement 
Solutions for Sustained Epidemic Control Project

AGENCY: Health Resources and Services Administration (HRSA), Department 
of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: HRSA has decided not to provide funding for HRSA-20-083 
Quality Improvement Solutions for Sustained Epidemic Control Project,

[[Page 62313]]

supported by the President's Emergency Plan for AIDS Relief (PEPFAR).

FOR FURTHER INFORMATION CONTACT: Austin Demby, Ph.D., MPH, Acting 
Director, Office of Global Health, Office of the Administrator, HRSA, 
5600 Fishers Lane, 09N09, Rockville, MD 20857, Phone: (301) 443-0581, 
Email: [email protected].

SUPPLEMENTARY INFORMATION:
    Justification: HRSA has decided not to award funding under HRSA-20-
083, Quality Improvement Solutions for Sustained Epidemic Control 
Project, which was published in Fiscal Year 2020. HRSA will consider 
the needs of the government and the program, and may publish an updated 
project Notice of Funding Opportunity for a new competitive cycle in 
Fiscal Year 2021.

    Authority:  United States PEPFAR authorized by Public Law 108-25 
(the United States Leadership Against HIV/AIDS, Tuberculosis and 
Malaria Act of 2003) [22 U.S.C. 7601, et seq.]; and Public Law 110-
293 (the Tom Lantos and Henry J. Hyde United States Global 
Leadership Against HIV/AIDS, Tuberculosis, and Malaria 
Reauthorization Act of 2008), as reauthorized and amended by Public 
Law 113-56 (the PEPFAR Stewardship and Oversight Act of 2013). See, 
e.g., 22 U.S.C. 7603 and 22 U.S.C. 151b-2(b)(1)(B), 2151b-2(c)(1), 
and 2151b-2(d)(6)(G)(ii).

Thomas J. Engels,
Administrator.
[FR Doc. 2020-21779 Filed 10-1-20; 8:45 am]
BILLING CODE 4165-15-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.